Nurosene will revolutionize how consumers approach their performance and wellness needs.
The Opportunity
1.5T Market
Health + Wellness
$10.5B by 2025
Performance
$14B by 2025
Self-Improvement
264M Affected Globally
Mental Health
The Nuro Solution
Nuro – The world’s first app that understands the underlying brain biology by using our proprietary Virtual Neural Scan.
Nuro – Will make recommendations that improve specific core neural networks and improve brain coherence.
Nurosene – Will own the world’s most advanced brain based population data set.
Nurosene – Will drive this data through our advanced AI platform – NetraMark’s NetraAI.
NetraAI – Will identify precision drugs and nutraceuticals and we will hold a carried interest in these candidates.
Investor Presentation
Board & Advisors
Press Releases
May 6 - Nurosene Announces Strategic Agreement with Brain Analysis Platform, Cove Neurosciences Inc.
April 19 - Nurosene Initiates Research on Nuro App in Collaboration with Dalhousie University
April 7 - Nurosene Appoints Seasoned Finance Executive Gino DeMichele to Board of Directors
March 1 - Nurosene Advances Brain Health with the Launch of its Science First Nuro App
February 23 - Nurosene Announces a Change in Leadership
February 10 - Nurosene & Cyclica Partner To Develop Novel Drugs For Neurodegenerative Diseases
February 4 - Nurosene Health Inc. Announces Change to its Board of Directors
Corporate Directory
Nurosene
[Head Office]
1655 Dupont St. #Suite 101
Toronto, ON M6P 3S9
investors@nurosene.com
Fasken Martineau DuMoulin LLP
[Legal]
2400 - 333 Bay St.
Toronto, ON M5H 2T6
416.366.8381
MNP LLP
[Auditors]
111 Richmond St. W Suite 300
Toronto, ON M5H 2G4
416.596.1711
Odyssey Trust
[Transfer Agent]
United Kingdom Building 323
409 Granville Street
Vancouver, BC V6C 1T2
1.833.392.7716